Article
Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen.
G3 (Bethesda, Md.) - 9 Feb 2021
Goh Corinna Jie Hui, Wong Jin Huei, El Farran Chadi, Tan Ban Xiong, Coffill Cynthia R, Loh Yuin-Hain, Lane David, Arumugam Prakash
Abstract excerpt
Vemurafenib is a BRAF kinase inhibitor (BRAFi) that is used to treat melanoma patients harboring the constitutively active BRAF-V600E mutation. However, after a few months of treatment patients often develop resistance to vemurafenib leading to disease progression. Sequence analysis of drug-resistant tumor cells and functional genomic screens has identified several genes that regulate vemurafenib resistance....
Topics
- CRISPR-Cas Systems
- Cell Line, Tumor
- Clustered Regularly Interspaced Short Palindromic Repeats
- Drug Resistance, Neoplasm
- Humans
- Melanoma
- Mutation
- Vemurafenib